User: Guest

CLINICAL MICROBIOLOGY INSTRUMENTS AND REAGENTS

Global Market Trajectory & Analytics

MCP13302

VALIDATED EXECUTIVE ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

9152

Interactions with Platform & by Email *

INTERACTIONS

1281

Unique # Participated *

PARTICIPANTS

273

Responses Validated *

VALIDATIONS

123

* Login to view program details and full enterprise executive list.


  •  DATE

    JUNE 2020

  •  TABLES

    309

  •  PAGES

    664

  •  EDITION

    6

  •  PRICE

    USD $4950


GLOBAL EXECUTIVE SURVEY

Impact of Pandemic & Economic Slowdown

Monitor Market Dynamics!
Early March 2020, we reached out to senior enterprise executives who are driving strategy, business development, marketing, sales, product management, technology and operations at competitive firms worldwide. Our ongoing survey is focused on how this will this affect their business ecosystems. We invite you to participate in our survey and add to collective perspectives. Market movements are tracked for 2020, 2021 and broadly for the period of 2022 through 2025. Critical changes are monitored dynamically for the rest of this year. Updated analytics will reflect new and evolving market realities. Our first update scheduled for May 2020 and another in the Fall. Clients receive complimentary updates during 2020. If your company is a recent client for this project, we may have already reached out to your colleagues to participate in our program. If you're an active player in the space but hasn't yet subscribed to our project, we invite you to participate and share your perspectives. Please sign-up here.

As the corona virus surges across the globe, vigilance and elevated corona virus response activities will continue unabated. Laboratories the world over are busy and have been kept open all through the lockdown period as the race to test for infections and develop drugs, diagnostics, and vaccines continues with undiminished fervor. While industrial laboratories were shut down as part of the containment measures, microbiology labs, virology labs, clinical testing labs, research labs and academic labs have been actively involved in the global fight against the pandemic. Against this backdrop, the global market for Clinical Microbiology will reach a projected market size of US6.1 billion by the year 2027, trailing a CAGR of 6.4%. As COVID-19 antiviral drugs and vaccine development intensifies, billions of dollars are being invested in over 100 vaccine candidates forcing labs to work at full and extended capacity. Scientists across the worlds are working away in labs analyzing data and finding newer ways to advance their corona virus research projects. By isolating and differentiating microorganisms, clinical microbiology plays a pivotal role in supporting the global response against COVID-19. The ability to quickly and easily classify a deadly virus like COVID-19 in minutes is of immense importance in planning and mobilizing medical needs.

Efforts to carry out a complete genome sequencing of SARS-CoV-2 are being ramped up, while the world waits in agony for medical solutions against the infection. Cracking the COVID-19 genome signature is an essential arsenal in the toolkit for diagnostics, vaccine and drug development. With rapid and accurate diagnosis of SARS-CoV-2 expected to assist in the control of the outbreak, microbiology labs worldwide are racing to test billions of samples. The COVID-19 serology race is getting bigger and faster. Serology tests remain important as it supports community surveillance efforts by playing a key role in identifying individuals with past COVID-19 infections. Responding in droves are developers racing to develop new COVID-19 antibody tests, and laboratories preparing to test samples. The U. S. and Europe together account for a major chunk of the global market. Growth in the coming years will stem from developing countries in Asia Pacific, Latin America, and the Middle East, driven by increasing automation and growing use of rapid microbiological tests.

The healthcare and medical system in most parts of the world are in crisis after decades of neglect. With the pandemic exposing the under-preparedness of health systems worldwide, the healthcare industry has suddenly emerged into a key focus area. Governments worldwide have voiced plans to strengthen the healthcare system. Already governments have announced budgetary support to strengthen the health system`s response to COVID-19. From stepping up clinical research activities to constructing new hospitals and procuring critical care life support devices, several measures are being implemented. The world will need to double its healthcare coverage in the coming years. Countries worldwide will need to intensify efforts to expand healthcare services and increase spending to least an additional 1.5% to 2.0% of GDP on primary care than current spends to ensure universal health coverage by 2030. The scenario brings good news for the clinical microbiology market as it brings new opportunities for demand growth of instruments and reagents. Asia-Pacific is expected to emerge as the fastest growing market for automated and rapid microbiological tests. Emerging nations, such as China, India, and Brazil, present significant opportunities due to their constantly growing healthcare infrastructure. In the post COVID-19 period, Asia will record growth supported by the rising prevalence of various pathogenic diseases, need to accelerate microbiological testing and discovery of adapting and mutating bacterium. Currently, clinical microbiology is widely used in Asia to identify fungal, bacterial and parasitic infections. Focus on healthcare reforms, emphasis on controlling costs of public hospitals, continuous rise in number of patients at primary healthcare centers, and rapid growth of private hospitals will spur growth of independent clinical diagnostics automation.

» Product (Instruments, Reagents) » Disease Area (Respiratory Diseases, Bloodstream Infections, Gastrointestinal Diseases, Sexually Transmitted Diseases, Urinary Tract Infections, Other Disease Areas) » End-Use (Hospitals & Diagnostic Centers, Custom Lab Service Providers, Academic & Research Institutes)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

INSIDER ACCESS PRIVILEGES

Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.

  • A: 
    ACTIVE CLIENT
  • B: 
    INACTIVE CLIENT
  • C: 
    ACTIVE PANELIST
  • D: 
    INACTIVE PANELIST
  • E: 
    OPT-INS
  
REPORT INDEX PROJECT COMPENDIUM * EXPERT PANEL

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com